糖尿病视网膜病变治愈加速器:现代化分期与终点指标
Mary Tyler Moore Vision Initiative与眼科创新协作社区联合发起DRD治愈加速器,旨在现代化DRD的临床有意义分期系统和终点指标。2025年6月超过100名国际专家的工作坊强调需要基于视网膜神经血管单元的验证结构和功能终点,并优先考虑早期生物标志物和功能指标。
要点
- 强调基于视网膜神经血管单元的验证结构和功能终点
- 早期生物标志物包括视网膜非灌注、内层视网膜变薄和视网膜层紊乱
- 功能优先级包括对比敏感度、电生理和基于表现的移动参数
核心结论
- 该加速器旨在通过精准表型分型和机制 granularity 建立国际共识的稳健终点,加速DRD治愈疗法的开发。
研究设计与样本
- 2025年6月工作坊,涉及超过100名国际专家,由Mary Tyler Moore Vision Initiative和眼科创新协作社区联合发起。
主要发现
- 当前DRD分期存在局限性,早期生物标志物如视网膜非灌注、内层视网膜变薄和视网膜层紊乱受重视。
- 功能优先指标包括对比敏感度、电生理和基于表现的移动参数,反映真实世界视觉损害。
关键数值与推荐
- 早期生物标志物包括视网膜非灌注、内层视网膜变薄和视网膜层紊乱。
- 功能指标包括对比敏感度、电生理和基于表现的移动参数。
临床怎么用
- 采用精准表型分型分离特定分子致病通路,支持靶向药物重定位和治愈性疗法开发。
- 下一步包括前瞻性多中心研究、协调协议和基于患者相关结局的AI参考标准与终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The "Diabetic Retinal Disease (DRD) Cure Accelerator," a joint initiative by the Mary Tyler Moore Vision Initiative and the Collaborative Community on Ophthalmic Innovation, aims to modernize clinically meaningful staging systems and endpoints for DRD. During a June 2025 workshop involving over 100 international experts, participants emphasized the urgent need for validated structural and functional endpoints grounded in the retinal neurovascular unit. Current DRD staging limitations were highlighted alongside the importance of early biomarkers, including retinal nonperfusion, inner retinal thinning, and disorganization of retinal layers. Functional priorities included contrast sensitivity, electrophysiology, and performance-based mobility parameters that reflect real-world visual impairment. Beyond clinical staging, this approach facilitates precision phenotyping to isolate specific molecular pathogenic pathways driving disease in individual patients. Mechanistic granularity provides a foundation for discovery science, enabling targeted drug re-purposing and the development of curative therapeutics. Key next steps include prospective multicenter studies, harmonized protocols, and reference standards and endpoints for AI based on patient relevant outcomes. By integrating scientific, clinical, and patient-centered perspectives, this Accelerator seeks to establish an international consensus on robust endpoints. Ultimately, this precision-based approach aims to transform DRD diagnosis and treatment, accelerating the access of patients worldwide to therapies that reduce diabetes-related vision loss.
引用
- Sampani K, Fickweiler W, Markel DS, et al. Diabetic retinal disease cure accelerator: Modernizing staging and endpoints. Prog Retin Eye Res. 2026. PMID: 42173402. doi:10.1016/j.preteyeres.2026.101485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。